All In Biotech

NDA 022348 · Apotex

Caldolor

Ibuprofen · Intravenous · Nonsteroidal Anti-inflammatory Drug

Priority review

Last checked: Nov 19, 2026Latest source record: Jan 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Jun 11, 2009

Approved uses

5

Original approval plus efficacy supplements

Registered trials

910

162 Phase 3, 61 recruiting

FAERS reports

201,240

146,657 serious, 16,456 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS See full prescribing information for complete boxed warning Non-steroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. ( 5.1 ) CALDOLOR is contraindicated in the setting of coronary artery bypass graft (CABG) surgery. ( 4 , 5.1 ) NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or...

What it is approved for

From the label in effect Jan 29, 2026.

CALDOLOR is indicated in adults and pediatric patients aged 3 months and older for the: management of mild to moderate pain, including postoperative pain management of moderate to severe pain, including postoperative pain, as an adjunct to opioid analgesics reduction of fever CALDOLOR is a nonsteroidal anti-inflammatory drug indicated in adults and pediatric patients aged 3 months and older for the: Management of mild to moderate pain, including postoperative pain Management of moderate to severe pain, including postoperative pain, as an adjunct to opioid analgesics ( 1 ) Reduction of fever ( 1 )

Mechanism: Ibuprofen has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of CALDOLOR, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Ibuprofen is a potent inhibitor of prostaglandin synthesis in vitro. Ibuprofen concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because ibuprofen is an inhibitor of prostaglandin synthesis,...

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • CALDOLOR · IBUPROFEN 800MG/8ML (100MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • CALDOLOR · IBUPROFEN 800MG/200ML (4MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • CALDOLOR · IBUPROFEN 400MG/4ML (100MG/ML) · SOLUTION, INTRAVENOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Ibuprofen" as an intervention, any sponsor and status, largest first.

All 910 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective15,930
  • pain15,218
  • fatigue14,694
  • nausea13,725
  • headache12,243
  • arthralgia11,062
  • dyspnoea10,659
  • vomiting10,121
  • diarrhoea9,835
  • rash9,144
  • off label use8,772
  • dizziness8,294

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,609
20052,142
20062,049
20072,109
20081,779
20092,763
20103,973
20115,696
20127,072
20136,754
20146,567
20159,101
201612,510
201711,350
201815,600
201916,689
202015,485
202115,252
202214,645
202313,671
202412,643
202512,813
20268,959

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Caldolor (Ibuprofen)

2024 spending

$10K

Beneficiaries

36

73 claims

Per beneficiary

$270

$3.27 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$9,725

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,679 on PubMed

Sponsor: Apotex

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.